South Africa’s Department of Health and senior pharmaceutical industry leaders have announced a collaborative initiative aimed at addressing mounting pressures within the sector. Following a substantive meeting, government officials and industry representatives agreed to establish a formal, ongoing engagement framework to tackle critical issues affecting pharmaceutical sector challenges and healthcare delivery.
The meeting brought together Acting Director-General Professor Nicholas Crisp from the Department of Health alongside senior officials representing Trade, Industry and Competition; Science, Technology and Innovation; National Treasury; and the Presidency. Additional stakeholders including the Competition Commission, South African Health Products Regulatory Authority (SAHPRA), and the Medicines Pricing Committee participated in the discussions.
Addressing Pharmaceutical Sector Challenges Through Open Dialogue
“The meeting provided an opportunity for a frank and constructive exchange on the pressures facing the sector, including heightened global geopolitical uncertainty and global supply-chain disruptions. Industry outlined the practical impact of current conditions, while government shared the broad direction of its evolving localisation roadmap,” the DoH said in a statement.
“Participants recognised that, while the medium- and longer-term elements of the roadmap are being finalised and appropriate funding identified, several urgent matters require immediate attention and resolution. Government undertook to consider an extraordinary single exit price [SEP] adjustment, in line with existing domestic and geopolitical pricing pressures,” the statement added.
Structured Framework for Ongoing Collaboration
The parties established a formal, institutionalised engagement mechanism designed to meet regularly and ensure sustained dialogue. This framework aims to create predictability and transparency in addressing pharmaceutical sector challenges while maintaining focus on patient outcomes and healthcare system stability.
Priority Areas for Joint Action
The collaborative framework identified several critical focus areas requiring immediate and sustained attention:
Medicine Pricing and Affordability – Development of a fair, transparent, and predictable single exit price adjustment mechanism that serves dual objectives: ensuring medicine affordability for patients while supporting sustainable supply. Joint review of applicable regulations governing pricing mechanisms forms part of this priority.
Regulatory Strengthening and Industry Coordination – Continued development of SAHPRA’s regulatory capacity paired with structured engagement between regulators and industry. Early collaborative planning aims to minimize operational disruption, reduce unnecessary costs, support economic growth and export competitiveness, and ensure timely access to safe, effective, and quality medicines.
Manufacturing Investment and Export Development – Capital investment support and export incentives designed to stimulate greater pharmaceutical manufacturing investment within South Africa and advance the sector’s export ambitions. This includes targeted assistance for the distressed contract manufacturing subsector.
Public-Sector Procurement Reform – Implementation of transparent, predictable, and consistent procurement rules that support localisation objectives, ensure reliable medicine supply, and enable long-term business planning and contracting arrangements.
Alternative Reimbursement Models – Exploration of innovative reimbursement approaches that could enhance affordability of selected medicines for patients and healthcare systems.
Regulatory Efficiency – Removal of unnecessary regulatory burdens and implementation of measures reducing the cost of business operations, thereby supporting investment and more efficient pharmaceutical supply channels.
Investment Incentives – Development of a comprehensive incentive package aimed at sustaining current manufacturing capacity, attracting new sector investment, and strengthening local production and medicine security.
Government’s Commitment to Pharmaceutical Sector Challenges Resolution
The Department of Health statement said, “Government underscored its commitment and readiness to work closely with industry to build a stronger pharmaceutical future across the public and private sectors, in the best interests of patients and the country’s healthcare system.”
“The engagement reflects a shared recognition of the pharmaceutical sector’s importance to patient access, sustained medicine supply, public health, investment, employment and South Africa’s industrial-development objectives,” the statement added.
